| Literature DB >> 35456573 |
Xiangjie Di1,2, Xiao Liang1,3, Chao Shen1, Yuwen Pei1, Bin Wu1, Zhiyao He1,4.
Abstract
Carbohydrates, one of the most important compounds in living organisms, perform numerous roles, including those associated with the extracellular matrix, energy-related compounds, and information. Of these, polymeric carbohydrates are a class of substance with a long history in drug delivery that have attracted more attention in recent years. Because polymeric carbohydrates have the advantages of nontoxicity, biocompatibility, and biodegradability, they can be used in drug targeting, sustained drug release, immune antigens and adjuvants. In this review, various carbohydrate-based or carbohydrate-modified drug delivery systems and their applications in disease therapy have been surveyed. Specifically, this review focuses on the fundamental understanding of carbohydrate-based drug delivery systems, strategies for application, and the evaluation of biological activity. Future perspectives, including opportunities and challenges in this field, are also discussed.Entities:
Keywords: carbohydrate-based polymer; drug delivery; hydrogel; nanoparticle
Year: 2022 PMID: 35456573 PMCID: PMC9025897 DOI: 10.3390/pharmaceutics14040739
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.525
Figure 1Carbohydrates used in polymeric systems for drug delivery.
Figure 2The structure and different modifications of Xanthan gum.
Figure 3The mechanism of pH/redox-responsive delivery.
Figure 4The structure of dextran and its modification in drug delivery.
Figure 5Dextran used in RNA interference therapy.
Figure 6The structure of an alginate and its modification.
Figure 7Use of chitosan and alginate to protect insulin.
Figure 8The structure of gellan.
Figure 9The structure of Pullulan.
Figure 10The structure of mannan.
Figure 11NIR and pH responses of hyaluronic acid nanogels.
Figure 12The structure of agarose.
Figure 13The structure of guar gum.
The drugs used incorporating carbohydrate-based materials as scaffolds entering clinical trials.
| Code Name | Drug Name | Available Date | Highest Phase | Prescription/Indication Type | Condition | Organization | Related Basic Patent |
|---|---|---|---|---|---|---|---|
| PRV-111 | Cisplatin ChemoThin Wafer (Generic) | 6 November 2015 | Phase I/II | Orphan drug designation | Cancer, anus | Privo Technologies | US 2014234212 |
| IMF-001 | IMF-001 (Code) | 31 December 2010 | Phase I | Nanoparticles of cholesteryl hydrophobized pullulan | Cancer, esophagus | ImmunoFrontier | |
| CHP-NY-ESO-1 | CHP-NY-ESO-1 (Code) | 10 October 2006 | Phase I | Nanoparticles consist of cholesterol-bearing hydrophobized pullulan | Cancer, solid tumor | Ludwig Institute for Cancer Research | |
| CHP-HER2 | Cholesteryl hydrophobized polysaccharide-Her2 protein complex (Generic)CHP-HER2 (Code) | 3 November 2005 | Phase I | Nanoparticles consist of cholesterol-bearing hydrophobized pullulan | Cancer | Mie University Nagasaki University | |
| SHU-555AZK-132281 | Ferucarbotran (Generic) | 25 November 1994 | Launched 2001 | Superparamagnetic iron oxide covered with Dextrans | Cancer, liver | Bayer | WO 2006028129EP 2005970WO 2010049062US 2012095325WO 2012136813WO 2013177364 |
| [68Ga]Nanocolloid | [68Ga]Nanocolloid (Code) | 24 January 2019 | Clinical | Nanoparticles consist of Dextrans and gallium complexes | Cancer, prostate | Peter MacCallum Cancer Centre (Originator)University of Melbourne (Originator) |
Figure 14Application of the Maillard reaction in carbohydrate-modified preparations.